Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study

2018 Journal of viral hepatitis 25;1 (97-104)

The potential interaction between chronic hepatitis B (CHB) and nonalcoholic fatty liver disease (NAFLD), two of the most prevalent liver diseases worldwide, has not been well defined. We performed liver stiffness (LS) and controlled attenuation parameter (CAP) measurements using transient elastography in 1202 CHB patients. Of these, 601 steatotic patients were matched with nonsteatotic controls in a 1:1 ratio by age, gender, nucleoside analogue treatment status, and treatment duration. Severe fibrosis was defined according to EASL-ALEH criteria, and steatosis was defined as CAP >/=222 dB m(-1) . Anthropometric measurements and metabolic-related parameters were recorded. The mean age of the 1202 patients (51.4% male) was 51.8 years. 696 patients (57.9%) were on nucleoside analogues for a median duration of 76.2 months. Among treatment-naive patients, median serum HBV DNA was lower in steatotic individuals than in controls (3.0 vs 3.4 log IU mL(-1) , P

Pubmed : 28772340